Feed HALO
HA

Halozyme Therapeutics HALO · NASDAQ

$131.18 +0.88% (+$1.15)

Market cap
$14.9B
Enterprise value
$16.9B
P/E
36.0x
Forward P/E
13.9x
PEG
-
P/S
8.9x
P/FCF
18.5x
EV/EBITDA
23.6x
ROIC
27.4%
Gross margin
78.2%
Net margin
24.9%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
2.8x
Beta
0.88
Free float
98.9%

About the company

Halozyme Therapeutics, Inc. is a U.S.-based biotechnology company focused on developing innovative therapeutic agents and technologies that improve drug absorption. Founded in 1998 and headquartered in San Diego, California, Halozyme is best known for its Enhanze™ platform, which uses enzymes to accelerate the absorption of biologic drugs, enabling them to be administered in lower doses or over shorter periods. The company collaborates with numerous pharmaceutical and biotechnology firms to develop new therapeutic products.

Sector

Healthcare

Industry

Biotechnology

CEO

Helen I. Torley

Employees

423

Headquarters

San Diego

Valuation

Is today's price reasonable?

  • What to watch: You pay 36.0 USD for 1 USD of yearly profit, a lot for its sector.

Growth and estimates

Is it growing, and what comes next?

  • What speaks for it: Earnings per share grew by 21% a year over the last 3 years.
  • What speaks for it: Analysts expect revenue to grow by 35% this fiscal year.

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

  • What speaks for it: Out of every 100 USD of revenue, 25 USD is left as net profit.
  • What speaks for it: It earns 27 USD a year on every 100 USD of invested capital.

Financial health

Can it carry its debt?

  • What to watch: For every 100 USD of shareholders' equity it carries 1,495 USD of debt.

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy